TY - JOUR
T1 - Docetaxel Plus Cisplatin
T2 - An Active Combination Regimen in Non-Small-Cell Lung Cancer
AU - Gralla, Richard J.
AU - Cole, John T.
AU - Robertson, Carrie N.
AU - Marques, Carol B.
AU - Rittenberg, Cynthia N.
PY - 1997/12/1
Y1 - 1997/12/1
N2 - Docetaxel (Taxotere) is a semisynthetic taxoid that possesses significant activity as a single agent in the treatment of patients with non-small-cell lung cancer. In patients with advanced non-small-cell lung cancer who had previously failed cisplatin (Platinol)-based chemotherapy, 100 mg/m2 of docetaxel administered as an intravenous infusion over 1 hour, once every 3 weeks, produced a median response rate of 17% (of the intent-to-treat population) and median survival of 9 months. The present report describes the preliminary results from 3 phase II trials performed in the United States, France, and Australia, examining the combination of docetaxel and cisplatin in patients with advanced non-small-cell lung cancer. One trial (Australian) studied docetaxel administered as a 1-hour intravenous infusion followed by a 30-minute infusion of cisplatin on days 1, 22, and then every 3 weeks. The French and US trials administered docetaxel every 3 weeks, but gave cisplatin on days 1, 22, and then every 6 weeks. Major response rates ranged from 30% to 51% and median estimated survival ranged from 9 to 10.5 months. Based on the results of these trials, the recommended dose for future phase II and III trials in patients with advanced non-small-cell lung cancer is either 75 mg/m2 of docetaxel and 75 mg/m2 of cisplatin, or 65 mg/m2 of docetaxel and 100 mg/m2 of cisplatin, with docetaxel being administered once every 3 weeks and cisplatin on days 1, 22, and then every 6 weeks.
AB - Docetaxel (Taxotere) is a semisynthetic taxoid that possesses significant activity as a single agent in the treatment of patients with non-small-cell lung cancer. In patients with advanced non-small-cell lung cancer who had previously failed cisplatin (Platinol)-based chemotherapy, 100 mg/m2 of docetaxel administered as an intravenous infusion over 1 hour, once every 3 weeks, produced a median response rate of 17% (of the intent-to-treat population) and median survival of 9 months. The present report describes the preliminary results from 3 phase II trials performed in the United States, France, and Australia, examining the combination of docetaxel and cisplatin in patients with advanced non-small-cell lung cancer. One trial (Australian) studied docetaxel administered as a 1-hour intravenous infusion followed by a 30-minute infusion of cisplatin on days 1, 22, and then every 3 weeks. The French and US trials administered docetaxel every 3 weeks, but gave cisplatin on days 1, 22, and then every 6 weeks. Major response rates ranged from 30% to 51% and median estimated survival ranged from 9 to 10.5 months. Based on the results of these trials, the recommended dose for future phase II and III trials in patients with advanced non-small-cell lung cancer is either 75 mg/m2 of docetaxel and 75 mg/m2 of cisplatin, or 65 mg/m2 of docetaxel and 100 mg/m2 of cisplatin, with docetaxel being administered once every 3 weeks and cisplatin on days 1, 22, and then every 6 weeks.
UR - http://www.scopus.com/inward/record.url?scp=0030816111&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030816111&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0030816111
SN - 0890-9091
VL - 11
SP - 27
EP - 30
JO - ONCOLOGY
JF - ONCOLOGY
IS - 7 SUPPL.
ER -
